almus pharmaceuticals limited
almus pharmaceuticals limited Company Information
Company Number
05037422
Next Accounts
Jun 2025
Shareholders
amerisourcebergen international b.v.
Group Structure
View All
Industry
Other business support service activities n.e.c.
Registered Address
space 4th floor, 68 chertsey road, woking, surrey, GU21 5BJ
Website
http://allianceboots.comalmus pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ALMUS PHARMACEUTICALS LIMITED at £6.3m based on a Turnover of £5.6m and 1.13x industry multiple (adjusted for size and gross margin).
almus pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ALMUS PHARMACEUTICALS LIMITED at £11.4m based on an EBITDA of £1.4m and a 8.31x industry multiple (adjusted for size and gross margin).
almus pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ALMUS PHARMACEUTICALS LIMITED at £50m based on Net Assets of £23.4m and 2.13x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Almus Pharmaceuticals Limited Overview
Almus Pharmaceuticals Limited is a live company located in woking, GU21 5BJ with a Companies House number of 05037422. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in February 2004, it's largest shareholder is amerisourcebergen international b.v. with a 100% stake. Almus Pharmaceuticals Limited is a mature, mid sized company, Pomanda has estimated its turnover at £5.6m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Almus Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Almus Pharmaceuticals Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 2 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
2 Weak
Size
annual sales of £5.6m, make it larger than the average company (£3.8m)
£5.6m - Almus Pharmaceuticals Limited
£3.8m - Industry AVG
Growth
3 year (CAGR) sales growth of -56%, show it is growing at a slower rate (5.3%)
-56% - Almus Pharmaceuticals Limited
5.3% - Industry AVG
Production
with a gross margin of 100%, this company has a lower cost of product (38.1%)
100% - Almus Pharmaceuticals Limited
38.1% - Industry AVG
Profitability
an operating margin of 24.7% make it more profitable than the average company (6.1%)
24.7% - Almus Pharmaceuticals Limited
6.1% - Industry AVG
Employees
with 4 employees, this is below the industry average (23)
4 - Almus Pharmaceuticals Limited
23 - Industry AVG
Pay Structure
on an average salary of £48.5k, the company has an equivalent pay structure (£48.5k)
- Almus Pharmaceuticals Limited
£48.5k - Industry AVG
Efficiency
resulting in sales per employee of £1.4m, this is more efficient (£154.6k)
£1.4m - Almus Pharmaceuticals Limited
£154.6k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Almus Pharmaceuticals Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Almus Pharmaceuticals Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Almus Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 87 weeks, this is more cash available to meet short term requirements (24 weeks)
87 weeks - Almus Pharmaceuticals Limited
24 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 6.4%, this is a lower level of debt than the average (61.5%)
6.4% - Almus Pharmaceuticals Limited
61.5% - Industry AVG
ALMUS PHARMACEUTICALS LIMITED financials
Almus Pharmaceuticals Limited's latest turnover from September 2023 is £5.6 million and the company has net assets of £23.4 million. According to their latest financial statements, Almus Pharmaceuticals Limited has 4 employees and maintains cash reserves of £2.7 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Sep 2023 | Sep 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 5,572,000 | 4,287,000 | 52,360,677 | 63,822,468 | 105,026,561 | 220,379,155 | 240,295,042 | 160,560,395 | 136,823,000 | 59,408,000 | 8,811,000 | 2,925,000 | 2,444,000 | 1,836,000 |
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | 5,572,000 | 4,287,000 | 52,360,677 | 63,822,468 | 105,026,561 | 220,379,155 | 240,295,042 | 160,560,395 | 136,823,000 | |||||
| Admin Expenses | 4,194,000 | -655,000 | 3,314,891 | 3,346,965 | 3,312,993 | 3,788,999 | 4,396,506 | 8,906,795 | 6,036,000 | |||||
| Operating Profit | 1,378,000 | 4,942,000 | 49,045,786 | 60,475,503 | 101,713,568 | 216,590,156 | 235,898,536 | 151,653,600 | 130,787,000 | 52,677,000 | 6,612,000 | 928,000 | 606,000 | 11,000 |
| Interest Payable | 364,013 | 5,166,957 | 431,000 | 4,000 | 17,000 | |||||||||
| Interest Receivable | 810,000 | 138,000 | 20,848 | 1,085,718 | 9,186,647 | 3,785,598 | 1,128,055 | 418,844 | 408,000 | 112,000 | 1,000 | |||
| Pre-Tax Profit | 2,188,000 | 5,080,000 | 328,989,656 | 61,561,222 | 110,900,215 | 220,375,754 | 236,662,580 | 151,653,600 | 130,764,000 | 52,789,000 | 6,613,000 | 928,000 | 602,000 | -6,000 |
| Tax | -457,000 | -1,024,000 | -9,321,626 | 378,478 | -338,837 | 488,821 | -1,623,879 | 957,462 | -26,994,000 | -12,143,000 | -1,587,000 | -241,000 | -169,000 | -1,000 |
| Profit After Tax | 1,731,000 | 4,056,000 | 319,668,030 | 61,939,700 | 110,561,378 | 220,864,575 | 235,038,700 | 152,611,063 | 103,770,000 | 40,646,000 | 5,026,000 | 687,000 | 433,000 | -7,000 |
| Dividends Paid | 324,025,339 | 152,353,460 | 466,618,808 | 212,530,817 | 138,793,554 | 110,600,000 | ||||||||
| Retained Profit | 1,731,000 | 4,056,000 | -4,357,309 | -90,413,760 | -356,057,430 | 8,333,758 | 235,038,700 | 13,817,509 | -6,830,000 | 40,646,000 | 5,026,000 | 687,000 | 433,000 | -7,000 |
| Employee Costs | 2,163,419 | 2,125,732 | 2,039,483 | 2,225,623 | 1,964,902 | 2,753,339 | 4,201,000,000 | 2,184,000 | 1,359,000 | 1,265,000 | 1,074,000 | 893,000 | ||
| Number Of Employees | 4 | 2 | 14 | 14 | 13 | 16 | 17 | 14 | 10 | 8 | 6 | 5 | ||
| EBITDA* | 1,378,000 | 4,950,000 | 49,061,823 | 60,518,001 | 101,755,922 | 216,637,762 | 235,924,591 | 151,678,280 | 130,789,000 | 52,679,000 | 6,612,000 | 928,000 | 606,000 | 11,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Sep 2023 | Sep 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,120,790 | 86,000 | ||||||||||||
| Intangible Assets | 8,019 | 24,056 | 60,302 | 121,568 | 129,512 | 96,545 | 128,000 | |||||||
| Investments & Other | ||||||||||||||
| Debtors (Due After 1 year) | 25,000,000 | |||||||||||||
| Total Fixed Assets | 8,018 | 24,055 | 60,301 | 121,567 | 129,511 | 1,217,334 | 214,000 | 25,000,000 | ||||||
| Stock & work in progress | ||||||||||||||
| Trade Debtors | 12,000 | |||||||||||||
| Group Debtors | 22,126,000 | 19,189,000 | 17,549,514 | 26,143,051 | 104,467,336 | 544,476,749 | 289,265,844 | 51,660,859 | 52,232,000 | 21,096,000 | 2,732,000 | 1,924,000 | 1,289,000 | 663,000 |
| Misc Debtors | 205,000 | 642,000 | 273,434 | 68,959 | 25,843 | 212,530 | 27,588 | 23,228 | 24,000 | 10,252,000 | 5,670,000 | 27,000 | 37,000 | 40,000 |
| Cash | 2,700,000 | 2,935,000 | 2,014,273 | 177,211 | 91,888 | 1,700 | 2,903 | 4,000 | 55,000 | 58,000 | 33,000 | 56,000 | 178,000 | |
| misc current assets | 140,270 | 1,931,182 | 15,109,611 | |||||||||||
| total current assets | 25,031,000 | 22,766,000 | 20,516,398 | 26,389,223 | 104,585,068 | 544,831,251 | 291,224,615 | 66,796,603 | 52,260,000 | 31,403,000 | 8,460,000 | 1,984,000 | 1,394,000 | 881,000 |
| total assets | 25,031,000 | 22,766,000 | 20,524,416 | 26,413,278 | 104,645,369 | 544,952,818 | 291,354,126 | 68,013,937 | 52,474,000 | 56,403,000 | 8,460,000 | 1,984,000 | 1,394,000 | 881,000 |
| Bank overdraft | ||||||||||||||
| Bank loan | ||||||||||||||
| Trade Creditors | 310,000 | 335,000 | 344,800 | 74,573 | 58,148 | 170,025 | 118,017 | 55,894 | 63,000 | 130,000 | 85,000 | 120,000 | 139,000 | 58,000 |
| Group/Directors Accounts | 1,112,000 | 279,000 | 1 | 1 | 1 | 2,410,000 | 238,000 | 188,000 | 129,000 | 82,000 | ||||
| other short term finances | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| other current liabilities | 177,000 | 451,000 | 717,664 | 2,519,445 | 2,318,736 | 2,023,292 | 1,064,448 | 15,734,609 | 12,012,000 | 6,634,000 | 1,554,000 | 119,000 | 256,000 | 101,000 |
| total current liabilities | 1,599,000 | 1,065,000 | 1,062,465 | 2,594,018 | 2,376,884 | 2,193,318 | 1,182,466 | 15,790,505 | 12,075,000 | 9,174,000 | 1,877,000 | 427,000 | 524,000 | 241,000 |
| loans | 203,000 | |||||||||||||
| hp & lease commitments | ||||||||||||||
| Accruals and Deferred Income | ||||||||||||||
| other liabilities | ||||||||||||||
| provisions | ||||||||||||||
| total long term liabilities | 203,000 | |||||||||||||
| total liabilities | 1,599,000 | 1,065,000 | 1,062,465 | 2,594,018 | 2,376,884 | 2,193,318 | 1,182,466 | 15,790,505 | 12,075,000 | 9,174,000 | 1,877,000 | 427,000 | 524,000 | 444,000 |
| net assets | 23,432,000 | 21,701,000 | 19,461,951 | 23,819,260 | 102,268,485 | 542,759,500 | 290,171,660 | 52,223,432 | 40,399,000 | 47,229,000 | 6,583,000 | 1,557,000 | 870,000 | 437,000 |
| total shareholders funds | 23,432,000 | 21,701,000 | 19,461,952 | 23,819,261 | 102,268,485 | 542,759,500 | 290,171,661 | 52,223,432 | 40,399,000 | 47,229,000 | 6,583,000 | 1,557,000 | 870,000 | 437,000 |
| Sep 2023 | Sep 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 1,378,000 | 4,942,000 | 49,045,786 | 60,475,503 | 101,713,568 | 216,590,156 | 235,898,536 | 151,653,600 | 130,787,000 | 52,677,000 | 6,612,000 | 928,000 | 606,000 | 11,000 |
| Depreciation | ||||||||||||||
| Amortisation | 8,000 | 16,037 | 42,498 | 42,354 | 47,606 | 26,055 | 24,680 | 2,000 | 2,000 | |||||
| Tax | -457,000 | -1,024,000 | -9,321,626 | 378,478 | -338,837 | 488,821 | -1,623,879 | 957,462 | -26,994,000 | -12,143,000 | -1,587,000 | -241,000 | -169,000 | -1,000 |
| Stock | ||||||||||||||
| Debtors | 2,500,000 | 2,008,051 | -8,389,062 | -78,281,169 | -440,196,099 | 255,395,847 | 237,609,344 | -571,912 | -4,092,000 | 47,946,000 | 6,451,000 | 613,000 | 635,000 | 703,000 |
| Creditors | -25,000 | -9,800 | 270,227 | 16,425 | -111,877 | 52,008 | 62,122 | -7,106 | -67,000 | 45,000 | -35,000 | -19,000 | 81,000 | 58,000 |
| Accruals and Deferred Income | -274,000 | -266,664 | -1,801,781 | 200,709 | 295,444 | 958,844 | -14,670,161 | 3,722,609 | 5,378,000 | 5,080,000 | 1,435,000 | -137,000 | 155,000 | 101,000 |
| Deferred Taxes & Provisions | ||||||||||||||
| Cash flow from operations | -1,878,000 | 1,641,485 | 46,597,705 | 139,394,782 | 541,796,751 | -37,258,412 | -17,916,671 | 156,923,157 | 113,198,000 | -2,285,000 | -26,000 | -82,000 | 38,000 | -534,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | ||||||||||||||
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | ||||||||||||||
| Group/Directors Accounts | 833,000 | 278,999 | 1 | 1 | -2,410,000 | 2,172,000 | 50,000 | 59,000 | 47,000 | 82,000 | ||||
| Other Short Term Loans | ||||||||||||||
| Long term loans | -203,000 | 203,000 | ||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||||
| other long term liabilities | ||||||||||||||
| share issue | ||||||||||||||
| interest | 810,000 | 138,000 | 20,848 | 1,085,718 | 9,186,647 | 3,785,598 | 764,042 | -4,748,113 | -23,000 | 112,000 | 1,000 | -4,000 | -17,000 | |
| cash flow from financing | 1,643,000 | -1,399,953 | 20,849 | 13,050,253 | -75,246,938 | 248,039,679 | 3,673,571 | -6,741,189 | -2,433,000 | 2,284,000 | 51,000 | 59,000 | -160,000 | 712,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -235,000 | 920,727 | 1,837,062 | 85,323 | 90,188 | 1,700 | -2,903 | -1,097 | -51,000 | -3,000 | 25,000 | -23,000 | -122,000 | 178,000 |
| overdraft | ||||||||||||||
| change in cash | -235,000 | 920,727 | 1,837,062 | 85,323 | 90,188 | 1,700 | -2,903 | -1,097 | -51,000 | -3,000 | 25,000 | -23,000 | -122,000 | 178,000 |
almus pharmaceuticals limited Credit Report and Business Information
Almus Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for almus pharmaceuticals limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other mid companies, companies in GU21 area or any other competitors across 12 key performance metrics.
almus pharmaceuticals limited Ownership
ALMUS PHARMACEUTICALS LIMITED group structure
Almus Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
AMERISOURCEBERGEN CORPORATION
#0155037
AMERISOURCEBERGEN INTERNATIONAL BV
#0154290
2 parents
ALMUS PHARMACEUTICALS LIMITED
05037422
almus pharmaceuticals limited directors
Almus Pharmaceuticals Limited currently has 3 directors. The longest serving directors include Ms Careen Snadden (Mar 2017) and Mr Nicholas Cossins (Feb 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Careen Snadden | United Kingdom | 58 years | Mar 2017 | - | Director |
| Mr Nicholas Cossins | United Kingdom | 43 years | Feb 2023 | - | Director |
| Mr Axel Viaene | England | 51 years | Feb 2023 | - | Director |
P&L
September 2023turnover
5.6m
+30%
operating profit
1.4m
-72%
gross margin
100%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
September 2023net assets
23.4m
+0.08%
total assets
25m
+0.1%
cash
2.7m
-0.08%
net assets
Total assets minus all liabilities
Similar Companies
almus pharmaceuticals limited company details
company number
05037422
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
February 2004
age
21
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
September 2023
previous names
N/A
accountant
-
auditor
DELOITTE LLP
address
space 4th floor, 68 chertsey road, woking, surrey, GU21 5BJ
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
almus pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to almus pharmaceuticals limited.
almus pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ALMUS PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
almus pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
